Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C5a anaphylatoxin chemotactic receptor 1 (C5AR1), also known as CD88, is a G protein-coupled receptor (GPCR) that serves as the primary receptor for complement component 5a (C5a), a potent pro-inflammatory peptide generated during activation of the complement system. It plays a central role in mediating immune and inflammatory responses. Activation leads to chemotaxis, cytokine release and modulation of cellular processes. Dysregulation is implicated in various diseases.
Agonists stimulate C5AR1, activating G proteins and downstream signaling pathways (e.g., calcium mobilization, ERK1/2 phosphorylation). Antagonists block C5a binding and subsequent receptor activation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C5a anaphylatoxin chemotactic receptor 1 (C5AR1).